PMC:6723065 / 72615-73141 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/6723065","sourcedb":"PMC","sourceid":"6723065","source_url":"https://www.ncbi.nlm.nih.gov/pmc/6723065","text":"CVT-301 l-dopa inhalation powder Change from Pre-dose in the UPDRS Part III Score at 30 min post-dose at 12 weeks for CVT-301 high dose versus placebo UPDRS motor score change from pre-dose to 30 min post-dose was −5.91 (SE 1.50, 95% CI −8.86 to −2.96) for the placebo group and −9.83 (1.51; −12.79 to −6.87) for the CVT-301 84 mg group (between-group difference −3.92 (−6.84 to −1.00); p = 0.0088) CVT-301 (Inbrija) is approved for the intermittent treatment of OFF episodes in PD patients treated with Carbidopa/Levodopa","divisions":[{"label":"td","span":{"begin":0,"end":8}},{"label":"td","span":{"begin":9,"end":33}},{"label":"td","span":{"begin":35,"end":152}},{"label":"td","span":{"begin":154,"end":401}}],"tracks":[]}